B
BioAtla, Inc. (BCAB)
NCM – Real Time Price. Currency in USD
3.68
+0.13 (3.66%)
At close: Jun 26, 2026, 4:00 PM EDT
3.68
0.00 (0.00%)
After-hours: Jun 26, 2026, 5:13 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
3.68
+0.13 (3.66%)
At close: Jun 26, 2026, 4:00 PM EDT
3.68
0.00 (0.00%)
After-hours: Jun 26, 2026, 5:13 PM EDT
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Cathy Chang Ph.D. | Senior Vice President of Research & Development |
| Dr. Eric L. Sievers M.D. | Chief Medical Officer |
| Dr. Gerhard Frey Ph.D. | Senior Vice President of Technology Development |
| Dr. Jay M. Short Ph.D. | Co-Founder, CEO & Chairman |
| Lisa M. Pelton | Accounting Manager |
| Ms. Monica Sullivan | Senior Vice President of Intellectual Property & Contracts |
| Date | Type | Document |
|---|---|---|
| 2026-06-03 | DEFA14A | bcab_defa_14a_2026_-_not.htm |
| 2026-06-03 | DEF 14A | bcab-20260603.htm |
| 2026-05-15 | 10-Q | bcab-20260331.htm |
| 2026-04-29 | 10-K/A | bcab-20251231.htm |
| 2026-04-02 | 8-K | bcab-20260402.htm |
| 2026-03-31 | S-8 | bcab-20260331.htm |
| 2026-03-31 | 8-K | bcab-20260331.htm |
| 2026-03-31 | 10-K | bcab-20251231.htm |
| 2026-03-23 | 8-K | bcab-20260317.htm |
| 2026-03-02 | DEFA14A | n5620_x3-defa14a.htm |
| Ms. Sheri Lydick | Chief Commercial Officer |
| Ms. Susie Melody | Senior Vice President of Human Resources |